

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sunho Biologics, Inc.

盛禾生物控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2898)

**FURTHER SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO
THE DELAY IN PUBLICATION OF THE ANNUAL RESULTS
ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025
AND
CONTINUED SUSPENSION OF TRADING**

This announcement is made by Sunho Biologics, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) and Rule 13.49(3)(i) of the Rules (the “**Listing Rules**”) Governing the Listing of the Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

References are made to the announcements (the “**Announcements**”) published by the Company dated March 27, 2026, March 30, 2026 and April 1, 2026 in relation to (1) the delay in publication of the 2025 Annual Results; (2) postponement of Board Meeting; and (3) suspension of trading. Unless otherwise stated, capitalized terms shall have the same meanings as those refined in the Announcements.

REASONS FOR THE DELAY IN PUBLICATION OF THE 2025 ANNUAL RESULTS

As disclosed in the Announcements, to complete the 2025 Annual Audit, the Auditor was in the course of collecting the documentation and information in relation to matters (the “**Matters**”) arising from several service agreements entered into by the Group (the “**Service Agreements**”) and the corresponding upfront payments (the “**Upfront Payments**”).

To address the Matters more precisely, the Company has engaged an independent professional advisor (the “**Independent Advisor**”) to perform an agree-upon procedures (the “**AUPs**”) on the Matters. The working scope of the AUPs covered, among others, the business rational and factual circumstances relating to the Service Agreements and the Upfront Payments, as well as the approval procedures and internal control procedures of the Service Agreements. As of the date of this announcement, procedures of the AUPs are ongoing. The Company would like to provide additional information about the reasons for the delay in the publication of the 2025 Annual Results, based on the information currently available, as following:

1. In order to pursue potential business development and capital market opportunities, in the second half of 2025, Sunho (HK) Limited (“**Sunho HK**”), a wholly-owned subsidiary of the Company, entered into the Service Agreements with four service providers (the “**Service Providers**”), primarily related to (i) providing advices and services related to the Group’s strategic planning and business development; and (ii) providing corporate financing advices and services to support the Group’s long-term development, for terms ranging from half a year to approximately three years.
2. Pursuant to the terms of the Service Agreements, Sunho HK made the Upfront Payments in a total amount of US\$15.3 million by the end of December 2025.
3. In light of the current market uncertainties, the Board considers that the strategy to pursue business development and capital market opportunities should be adjusted. Accordingly, all Service Agreements have been terminated pursuant to their respective terms, and the Upfront Payments have been refunded in full as of the date of this announcement.

As the Service Agreements have been terminated and the Upfront Payments have been refunded in full, the Directors are of the view that the Matters had no material adverse impact on the Group’s business operations and financial conditions. Notwithstanding the above, the Board recognizes the importance of maintaining rigorous corporate governance. Accordingly, the Company has engaged both the Independent Advisor to perform a specific internal control assessment regarding the Matters, and a separate independent internal control consultant to assist the Board in conducting a comprehensive review of the Group’s internal control systems to identify and address internal control issues in connection with the Matters. As of the date of this announcement, the abovementioned specific internal control assessment and comprehensive internal control review are still ongoing.

As of the date of this announcement, the Company is still coordinating with the Auditor to resolve the Matters and complete the 2025 Annual Audit as soon as possible. After taking into account the current situation, it is expected that the 2025 Annual Results will be published by April 30, 2026, subject to completion of all outstanding works of the 2025 Annual Audit.

The Company noticed the requirements under Rule 13.49(3) of the Listing Rules. Taking into account of the above, pending the resolving of the Matters, the Board was (and is still) of the view that it would not be appropriate for the Company to publish the unaudited management accounts of the Group for the year ended December 31, 2025 at this stage as it may not accurately reflect the financial performance and position of the Group and may confuse the shareholders and potential investors of the Company.

CONTINUED SUSPENSION OF TRADING

Trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on April 1, 2026 and will continue to be suspended pending the publication of the 2025 Annual Results by the Company.

Shareholders and potential investors of the Company are advised to exercise due caution when dealing in the securities of the Company. When in doubt, Shareholders and potential investors of the Company are advised to seek advice from professional or financial advisers.

By order of the Board
Sunho Biologics, Inc.
Mr. ZHANG Feng
Chairman and executive Director

Hong Kong, April 21, 2026

As at the date of this announcement, the executive Directors are Mr. ZHANG Feng and Ms. JIANG Xiaoling; the non-executive Director is Mr. FAN Rongkui; and the independent non-executive Directors are Mr. CHAN Heung Wing Anthony, Ms. FENG Lan and Mr. SHI Luwen.